7 recruiting. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 7 |
| Phase 2 | 1 | Recruiting 1 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma RC19D2 cell injection - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Recruiting | Beijing Yongtai Ruike Biotechnology Company Ltd | 25 | 2023-09-05 | 2024-08-27 |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2022-11-03 | 2026-09-10 |
Lymphoma, Large B-Cell, Diffuse (7) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · HIV Infections (1) · Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, Non-Hodgkin (6) · Lymphoma, B-Cell (5) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, B-Cell (2)
Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · Biopsy (3) · Cyclophosphamide (3) · fludarabine (3) · Leukapheresis (2) · Bendamustine Hydrochloride (1) · CTL019 chimeric antigen receptor (1) · Nivolumab (1) · Whole-Body Irradiation (1) · axicabtagene ciloleucel (1) · decitabine and cedazuridine drug combination (1) · ibrutinib (1) · tisagenlecleucel (1) · zanubrutinib (1)
AIDS Malignancy Consortium (1) · Beijing Yongtai Ruike Biotechnology Company Ltd (1) · City of Hope Medical Center (1) · Mayo Clinic (1) · Nathan Denlinger (1) · National Cancer Institute (NCI) (1) · Yazeed Sawalha (1)
United States (6) · China (1)
Ariela Noy (1) · Catherine S Diefenbach (1) · Geoffrey Shouse (1) · Mohamed A. Kharfan-Dabaja, M.D., M.B.A. (1) · Nathan Denlinger, DO (1) · Yazeed Sawalha (1)
P01CA229086 (1), P30CA016087 (1), P30CA033572 (1), UM1CA121947 (1)